论文部分内容阅读
①治疗组:中度以上发作的支气管哮喘病人26例。其中男16例,女10例,年龄20～62岁,平均年龄45岁。持续状态12人,其他14人。均在常规治疗基础上加用山莨菪碱治疗,其中哮喘持续状态给予10～20mg静脉点滴,每日1～2次。其他发作口服10mg,1日3次,夜间发作较重者睡前加服10mg。②对照组:中度以上发作的哮喘病人30例,其中男21例,女9例,年龄20～56岁,平均年龄38岁,常规应用茶碱类、糖皮质激素及β_2受体兴奋剂治疗,30例病人中,哮喘持续状态14人,其他16人。
① treatment group: moderate or more episodes of bronchial asthma in patients with 26 cases. Including 16 males and 10 females, aged 20 to 62 years, with an average age of 45 years. Persistent state of 12 people, the other 14 people. All patients were treated with Anisodamine on the basis of routine treatment, and the continuous state of asthma was given intravenously 10 ~ 20mg once or twice daily. Other episodes of oral 10mg, on the 1st 3 times, heavier night attack before going to bed plus 10mg. ② Control group: 30 cases of moderate and severe asthma attack, including 21 males and 9 females, aged 20 to 56 years, mean age 38 years old, routine use of theophylline, glucocorticoid and β 2 receptor agonist treatment Among the 30 patients, 14 were asthmatic and 16 were other.